Clin2
NCT07557927Possibly a fitNot yet recruiting

Dihydroartemisinin for discoid lupus erythematosus skin disease

Discoid Lupus Erythematosus

Treatments studied

Part of Skin clinical trials.

This trial tests a new tablet called dihydroartemisinin to treat discoid lupus erythematosus (DLE), a skin condition where the immune system causes scarring rashes, usually on the face and ears. The study compares this new drug to a standard treatment to see which works better and is safer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Age 18–65 years old
  • Diagnosed with discoid lupus erythematosus (DLE, a skin form of lupus) with a skin biopsy within the last 5 years
  • Body weight at least 45 kg (about 99 lbs)
  • Moderate to severe DLE skin involvement at screening
  • Normal liver, kidney, and blood cell counts (within safe limits)
  • No recent use of antimalarial drugs, strong steroids, or immune-suppressing medications

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06261021Recruiting· Phase 2
Ruxolitinib cream for discoid lupus study

This trial tests a cream (ruxolitinib) on discoid lupus skin lesions. It aims to see if the cream can reduce DLE symptoms in adults.

Fredericton, New Brunswick
NCT07440537Recruiting· Phase 2
Testing ICP-488 for active cutaneous lupus (skin lupus)

This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.

Hefei, Anhui
NCT07509892Recruiting· Phase 2
Testing TQH3906 for people with active lupus

This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.

Bengbu, Anhui
NCT07136389Recruiting· Phase 1
Testing 2 drugs for active lupus skin disease

This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.

Saint Petersburg
NCT07007078Recruiting· Early Phase 1
Dihydroartemisinin for acne vulgaris

This study tests if a medicine called dihydroartemisinin (a type of artemisinin, often used for malaria) can help treat acne when applied to the skin. It's a small early-phase trial for people with acne vulgaris.

Shanghai, Shanghai Municipality
NCT07355218Recruiting· Phase 3
Testing enpatoran for lupus skin problems

This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.

Upland, California

Hear when a new Discoid Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.